calcium binding protein 39Genealiases: CGI-66 · MO25
Q-omics provides the consensus-scored CAB39 profile across patient tissues and cancer cell-line models. CAB39 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAB39 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, CAB39 protein abundance shows 25,411 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where CAB39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAB39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAB39 survival associations across molecular data types. CAB39 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAB39 RNA expression–survival associations across cancer types. High CAB39 expression shows unfavorable associations in PAAD, ACC, HNSC and UVM, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAB39 RNA expression.
This table summarizes CAB39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CAB39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAB39 shows lower tumor expression in KICH, KIRC and COAD and higher tumor expression in LIHC, HNSC and CHOL. The KICH box plot shows higher CAB39 RNA expression in normal versus tumor tissue (log2 FC = −1.086, t-test p < 0.001).
This table shows molecular features associated with CAB39 in patient tissues and cancer cell lines. In patient samples, CAB39 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAB39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
